Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NeoGenomics ( (NEO) ) has shared an announcement.
On December 23, 2025, NeoGenomics’ board accepted the resignation of long-serving director Dr. Alison L. Hannah, effective December 31, 2025, and appointed diagnostics and lab services veteran John P. “Jack” Kenny to the board effective January 1, 2026, with his term running until the 2026 annual shareholders’ meeting. Kenny, a former president and CEO of Meridian Bioscience with more than three decades of executive and commercial experience at major diagnostics and healthcare companies, is expected to bolster NeoGenomics’ strategic focus on next-generation cancer testing such as NGS and MRD, reinforcing the company’s position in hematology cancer testing and supporting its plans for the next phase of growth while maintaining standard independent-director compensation and governance practices.
The most recent analyst rating on (NEO) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.
Spark’s Take on NEO Stock
According to Spark, TipRanks’ AI Analyst, NEO is a Neutral.
NeoGenomics shows strong clinical revenue growth and positive technical momentum, but faces significant profitability and cash flow challenges. The valuation remains a concern due to negative earnings, and while the earnings call provided positive future prospects, the current financial struggles weigh heavily on the overall score.
To see Spark’s full report on NEO stock, click here.
More about NeoGenomics
NeoGenomics, Inc., headquartered in Fort Myers, Florida, is a premier cancer diagnostics company specializing in cancer genetics testing and information services. The company offers a comprehensive oncology-focused testing menu across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers and pharmaceutical firms through a network of CAP-accredited and CLIA-certified laboratories in the United States and a CAP-accredited full-service lab in Cambridge, United Kingdom.
Average Trading Volume: 3,194,338
Technical Sentiment Signal: Hold
Current Market Cap: $1.59B
See more insights into NEO stock on TipRanks’ Stock Analysis page.